# Selenium Cognition Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/selenium-cognition-meta-analysis-evidence-review
Category: evidence-review
Summary: Selenium Cognition Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed 
Last reviewed: 2026-07-30
Reviewed by: Migaku Evidence Review
# Selenium Cognition Meta-analysis: What the Evidence Says

## Quick Answer

Selenium Cognition Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Interactions Between Blood Nutritional Biomarkers and Apolipoprotein E ε4 in the Progression of Mild Cognitive Impairment in Alzheimer’s Disease | narrative review | 3 | 2026-04-16 | 10.3390/nu18081263 |
| Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits | preclinical study | 4 | 2026-06-03 | 10.1007/s13668-026-00776-y |

## What The Sources Report

- In the late-onset groups, the apolipoprotein E (APOE) gene, the strongest and most consistently replicated genetic risk factor, is associated with AD. [Lawal Rasheedat (2026); evidence level 3]
- The ε4 allele increases the likelihood of developing AD and is associated with greater neuroinflammation and impaired lipid transport. [Lawal Rasheedat (2026); evidence level 3]
- Importantly, these biological changes manifest most meaningfully through declines in functional capacity, including reduced muscle strength, impaired metabolic regulation, diminished cognitive performance, and increased disease risk. [Kurtz Jennifer A. (2026); evidence level 4]
- This article aims to synthesize evidence from human studies evaluating dietary supplements that directly or indirectly modulate the recognized hallmarks of aging, such as mitochondrial dysfunction, oxidative stress, inflammation, and proteostasis. [Kurtz Jennifer A. (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For selenium cognition meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Lawal Rasheedat (2026). Interactions Between Blood Nutritional Biomarkers and Apolipoprotein E ε4 in the Progression of Mild Cognitive Impairment in Alzheimer’s Disease. DOI: 10.3390/nu18081263. PMCID: PMC13119481. PMID: 42075076. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13119481/
- Kurtz Jennifer A. (2026). Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits. DOI: 10.1007/s13668-026-00776-y. PMCID: PMC13233893. PMID: 42234350. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13233893/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.